Amedeo Smart

Free Medical Literature Service


 

Amedeo

Colorectal Neoplasms

  Free Subscription

Articles published in
Ann Oncol
    August 2017
  1. WHITE NM, Maher CA
    The potential use of lncRNAs found in the 8q24 region as biomarkers for colon cancer.
    Ann Oncol. 2017;28:1688-1689.
    >> Share

  2. OZAWA T, Matsuyama T, Toiyama Y, Takahashi N, et al
    CCAT1 and CCAT2 long noncoding RNAs, located within the 8q.24.21 'gene desert', serve as important prognostic biomarkers in colorectal cancer.
    Ann Oncol. 2017;28:1882-1888.
    >> Share

    May 2017
  3. WILLIS JA, Vilar E
    Refining Prognosis in Early-Stage Colorectal Cancer: One or multiple genes at a time?
    Ann Oncol. 2017 May 26. doi: 10.1093.
    >> Share

  4. SUNAKAWA Y, Tsuji A, Fujii M, Ichikawa W, et al
    No benefit from the addition of anti-EGFR antibody in all right-sided metastatic colorectal cancer?
    Ann Oncol. 2017 May 5. doi: 10.1093.
    >> Share

  5. DIENSTMANN R, Mason MJ, Sinicrope FA, Phipps AI, et al
    Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study.
    Ann Oncol. 2017;28:1023-1031.
    >> Share

  6. SUENAGA M, Schirripa M, Cao S, Zhang W, et al
    Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer.
    Ann Oncol. 2017;28:1015-1022.
    >> Share

  7. AUCLIN E, Zaanan A, Vernerey D, Douard R, et al
    Subgroups and prognostication in stage III colon cancer: future perspectives for adjuvant therapy.
    Ann Oncol. 2017;28:958-968.
    >> Share

    April 2017
  8. ROHR UP, Herrmann P, Ilm K, Zhang H, et al
    Prognostic value of MACC1 and proficient mismatch repair status for recurrence risk prediction in stage II colon cancer patients: the BIOGRID studies.
    Ann Oncol. 2017 Apr 28. doi: 10.1093.
    >> Share

  9. BOECKX N, Koukakis R, Op de Beeck K, Rolfo C, et al
    Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies.
    Ann Oncol. 2017 Apr 25. doi: 10.1093.
    >> Share

  10. BONNETAIN F, Borg C, Adams RR, Ajani JA, et al
    How health-related quality of life assessment should be used in advanced colorectal cancer clinical trials.
    Ann Oncol. 2017 Apr 18. doi: 10.1093.
    >> Share

  11. VIDAL J, Muinelo L, Dalmases A, Jones F, et al
    Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients.
    Ann Oncol. 2017 Apr 13. doi: 10.1093.
    >> Share

  12. ARNOLD D, Lueza B, Douillard JY, Peeters M, et al
    Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomised trials.
    Ann Oncol. 2017 Apr 12. doi: 10.1093.
    >> Share

  13. VIEIRA AR, Abar L, Chan D, Vingeliene S, et al
    Foods and beverages and colorectal cancer risk: a systematic review and meta-analysis of cohort studies, an update of the evidence of the WCRF-AICR Continuous Update Project.
    Ann Oncol. 2017 Apr 12. doi: 10.1093.
    >> Share

  14. KWAKMAN JJ, Simkens LH, van Rooijen JM, van de Wouw AJ, et al
    Randomised phase III trial of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer: SALTO study by the Dutch Colorectal Cancer Group.
    Ann Oncol. 2017 Apr 5. doi: 10.1093.
    >> Share

  15. FONT R, Espinas JA, Layos L, Martinez Villacampa M, et al
    Adherence to capecitabine in preoperative treatment of stage II and III rectal cancer: do we need to worry?
    Ann Oncol. 2017;28:831-835.
    >> Share

  16. BUDHATHOKI S, Iwasaki M, Yamaji T, Yamamoto H, et al
    Association of plasma concentrations of branched-chain amino acids with risk of colorectal adenoma in a large Japanese population.
    Ann Oncol. 2017;28:818-823.
    >> Share

    March 2017
  17. MA B, King AD, Leung L, Wang K, et al
    Identifying an early indicator of drug efficacy in patients with metastatic colorectal cancer - a prospective evaluation of circulating tumor cells, 18F-fluorodeoxyglucose positron-emission tomography and the RECIST criteria.
    Ann Oncol. 2017 Mar 30. doi: 10.1093.
    >> Share

  18. ROSPO G, Corti G, Crisafulli G, Novara L, et al
    Tracking colorectal cancer evolution in time and space.
    Ann Oncol. 2017 Mar 24. doi: 10.1093.
    >> Share

  19. SIRAVEGNA G, Sartore-Bianchi A, Mussolin B, Cassingena A, et al
    Tracking a CAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor.
    Ann Oncol. 2017 Mar 24. doi: 10.1093.
    >> Share

  20. GRASSELLI J, Elez E, Caratu G, Matito J, et al
    Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer.
    Ann Oncol. 2017 Mar 20. doi: 10.1093.
    >> Share

  21. FUCHS MA, Yuan C, Sato K, Niedzwiecki D, et al
    Predicted Vitamin D Status and Colon Cancer Recurrence and Mortality in CALGB 89803 (Alliance).
    Ann Oncol. 2017 Mar 15. doi: 10.1093.
    >> Share

    February 2017
  22. PILATI C, Taieb J, Balogoun R, Marisa L, et al
    CDX2 prognostic value in stage II/III resected colon cancer is related to CMS classification.
    Ann Oncol. 2017 Feb 27. doi: 10.1093.
    >> Share

  23. LONARDI S, Sobrero A, Rosati G, Di Bartolomeo M, et al
    Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial.
    Ann Oncol. 2017 Feb 23. doi: 10.1093.
    >> Share

  24. LOTE H, Spiteri I, Ermini L, Vatsiou A, et al
    Carbon dating cancer: defining the chronology of metastatic progression in colorectal cancer.
    Ann Oncol. 2017 Feb 23. doi: 10.1093.
    >> Share

  25. SANTINI D, Vincenzi B, Addeo R, Garufi C, et al
    Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?
    Ann Oncol. 2017 Feb 21. doi: 10.1093.
    >> Share

  26. DIENSTMANN R, Mason MJ, Sinicrope FA, Phipps AI, et al
    Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study.
    Ann Oncol. 2017 Feb 9. doi: 10.1093.
    >> Share

  27. SUENAGA M, Schirripa M, Cao S, Zhang W, et al
    Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer.
    Ann Oncol. 2017 Feb 9. doi: 10.1093.
    >> Share

    January 2017
  28. AUCLIN E, Zaanan A, Vernerey D, Douard R, et al
    Subgroups and Prognostication in Stage III Colon Cancer: Future Perspectives for Adjuvant Therapy.
    Ann Oncol. 2017 Jan 27. pii: mdx030. doi: 10.1093.
    >> Share

    December 2016
  29. TAIEB J, Balogoun R, Le Malicot K, Tabernero J, et al
    Adjuvant FOLFOX +/- cetuximab in full RAS and BRAF wildtype stage III colon cancer patients.
    Ann Oncol. 2016 Dec 28. pii: mdw687. doi: 10.1093.
    >> Share

  30. SCHUURHUIZEN CS, Braamse AM, Konings IR, Sprangers MA, et al
    Does severe toxicity affect global quality of life in patients with metastatic colorectal cancer during palliative systemic treatment? A systematic review.
    Ann Oncol. 2016 Dec 19. pii: mdw617. doi: 10.1093.
    >> Share

  31. SELIGMANN JF, Fisher D, Smith CG, Richman SD, et al
    Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: Analysis from 2530 patients in randomised clinical trials.
    Ann Oncol. 2016.
    >> Share

    November 2016
  32. PIETRANTONIO F, Miceli R, Rimassa L, Lonardi S, et al
    Estimating 12-weeks death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram.
    Ann Oncol. 2016.
    >> Share

  33. SWETS M, Breugom AJ, Gelderblom H, van de Velde CJ, et al
    Should rectal cancer located 10-15cm from the anal verge be defined as colon cancer.
    Ann Oncol. 2016.
    >> Share

    October 2016
  34. QUIDDE J, Hegewisch-Becker S, Graeven U, Lerchenmuller CA, et al
    Quality of life assessment in patients with metastatic colorectal cancer receiving maintenance therapy after first-line induction treatment: a preplanned analysis of the phase III AIO KRK 0207 trial.
    Ann Oncol. 2016.
    >> Share

  35. STELLOO E, Jansen AM, Osse EM, Nout RA, et al
    Practical guidance for mismatch repair-deficiency testing in endometrial cancer.
    Ann Oncol. 2016.
    >> Share

  36. MOORE M, Gill S, Asmis T, Berry S, et al
    Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy.
    Ann Oncol. 2016.
    >> Share

  37. DEENEN MJ, Meulendijks D
    Recommendation on testing for dihydropyrimidine dehydrogenase deficiency in the ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.
    Ann Oncol. 2016.
    >> Share

    September 2016

  38. appendix 5: Metastatic colorectal cancer (2): eUpdate published online August 2016 (www.esmo.org/Guidelines/Gastrointestinal-Cancers).
    Ann Oncol. 2016;27.
    >> Share


  39. appendix 4: Metastatic colorectal cancer (1): eUpdate published online September 2016 (www.esmo.org/Guidelines/Gastrointestinal-Cancers).
    Ann Oncol. 2016;27.
    >> Share

    August 2016
  40. LONARDI S, Sobrero A, Rosati G, Di Bartolomeo M, et al
    Phase III trial comparing 3 to 6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial.
    Ann Oncol. 2016.
    >> Share

  41. IMAOKA H, Toiyama Y, Fujikawa H, Hiro J, et al
    Circulating microRNA-1290 as a novel diagnostic and prognostic biomarker in human colorectal cancer.
    Ann Oncol. 2016.
    >> Share

    July 2016
  42. VARDY JL, Dhillon HM, Pond GR, Renton C, et al
    Fatigue in people with localized colorectal cancer who do and do not receive chemotherapy: a longitudinal prospective study.
    Ann Oncol. 2016.
    >> Share

  43. MEI Z, Duan C, Li C, Cui L, et al
    Prognostic role of tumor PIK3CAmutation in colorectal cancer: a systematic review and meta-analysis.
    Ann Oncol. 2016.
    >> Share

  44. VAN CUTSEM E, Cervantes A, Adam R, Sobrero A, et al
    ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.
    Ann Oncol. 2016.
    >> Share

    June 2016
  45. MODEST DP, Ricard I, Heinemann V, Hegewisch-Becker S, et al
    Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants - pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group.
    Ann Oncol. 2016.
    >> Share

  46. SOBRERO A
    A tribute to biologics in advanced colorectal cancer treatment.
    Ann Oncol. 2016.
    >> Share

    May 2016
  47. MICHL M, Stintzing S, Fischer von Weikersthal L, Decker T, et al
    CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).
    Ann Oncol. 2016.
    >> Share

  48. REN HG, Luu HN, Cai H, Xiang YB, et al
    Oral health and risk of colorectal cancer: results from three cohort studies and a meta-analysis.
    Ann Oncol. 2016.
    >> Share

  49. LUO HY, Xu RH
    Reply to "Safety profile of capecitabine as maintenance treatment after XELOX or FOLFOX in metastatic colorectal cancer patients" by C. Cremolini et al.
    Ann Oncol. 2016.
    >> Share

  50. YAMAZAKI K, Nagase M, Tamagawa H, Ueda S, et al
    Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G).
    Ann Oncol. 2016.
    >> Share

  51. CREMOLINI C, Moretto R, Masi G, Falcone A, et al
    Safety profile of capecitabine as maintenance treatment after XELOX or FOLFOX in metastatic colorectal cancer patients.
    Ann Oncol. 2016.
    >> Share

  52. SARTORE-BIANCHI A, Loupakis F, Argiles G, Prager GW, et al
    Challenging chemoresistant metastatic colorectal cancer: therapeutic strategies from the clinic and from the lab.
    Ann Oncol. 2016.
    >> Share

    February 2016
  53. ROSATI G, Ambrosini G, Barni S, Andreoni B, et al
    A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2-C colorectal carcinoma.
    Ann Oncol. 2016;27:274-80.
    >> Share

    December 2014
  54. SCHOFFSKI P, Besse B, Gauler T, de Jonge MJ, et al
    Efficacy and safety of biweekly intravenous administrations of the Aurora kinase inhibitor danusertib hydrochloride in independent cohorts of patients with advanced or metastatic breast, ovarian, colorectal, pancreatic, small cell and non-small cell l
    Ann Oncol. 2014.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016